Dalzell G W, Atkinson A B, Carson D J, Sheridan B
Metabolic Unit, Royal Victoria Hospital, Belfast, Northern Ireland.
Clin Endocrinol (Oxf). 1987 Feb;26(2):169-72. doi: 10.1111/j.1365-2265.1987.tb00773.x.
An 11-year-old male presented with a 2-year history of headache and lethargy. Serum PRL was elevated at 14,000 mU/l and computerized tomography showed a pituitary macroadenoma. Visual fields and fundi were normal and the testes showed early pubertal changes. There was normal responsiveness of serum cortisol but absence of GH response to hypoglycaemia. After bromocriptine therapy for 4 months serum PRL had fallen to 90 mU/l and the tumour was not visible on repeat computerized tomography. After 7 months treatment, repeat pituitary function testing showed restoration of GH response to hypoglycaemia. Treatment with bromocriptine was continued and there was spontaneous progression of normal puberty; the serum testosterone continued to rise, and height maintained the 50th centile. Bromocriptine therapy should be considered as initial therapy in the management of prolactinomas in prepubertal patients.
一名11岁男性,有2年头痛和嗜睡病史。血清催乳素升高至14,000 mU/l,计算机断层扫描显示垂体大腺瘤。视野和眼底正常,睾丸显示青春期早期变化。血清皮质醇反应正常,但生长激素对低血糖无反应。溴隐亭治疗4个月后,血清催乳素降至90 mU/l,重复计算机断层扫描未见肿瘤。治疗7个月后,重复垂体功能测试显示生长激素对低血糖的反应恢复。继续用溴隐亭治疗,青春期正常自然进展;血清睾酮持续升高,身高维持在第50百分位。溴隐亭治疗应被视为青春期前患者泌乳素瘤治疗的初始疗法。